The Acute Myeloid Leukemia Channel is supported with funding from BMS (Silver), and through an educational grant from Jazz Pharmaceuticals.
VJHemOnc is an independent medical education platform. Supporters, including channel supporters, have no influence over the production of content. The levels of sponsorship listed are reflective of the amount of funding given to support the channel.
ASH 2018 | Impact of MRD on FLT3-ITD AML
The predictive role of measurable residual disease (MRD) on survival across the hematology-oncology space is under intense investigation. Here, Mark Levis, MD, PhD, of the Sidney Kimmel Comprehensive Cancer Center, Baltimore, MD, discusses the impact of MRD on FLT3-ITD acute myeloid leukemia (AML). Dr Levis highlights how measuring MRD, using an NGS-based assay, revealed a potential association between MRD negativity and longer survival in patients with relapsed/refractory FLT3-ITD AML. This interview took place at the American Society of Hematology (ASH) 2018 Annual Meeting and Exposition in San Diego, CA.
